Perspective Therapeutics (NYSE:CATX) Given Outperform Rating at Wedbush

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a report released on Monday,RTT News reports. They presently have a $11.00 price target on the stock. Wedbush’s price target points to a potential upside of 323.08% from the stock’s current price.

A number of other research analysts also recently commented on the company. Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Scotiabank began coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 target price for the company. Oppenheimer reduced their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $24.00 to $5.00 in a research report on Monday, November 25th. Finally, HC Wainwright began coverage on Perspective Therapeutics in a report on Thursday. They issued a “buy” rating and a $10.00 target price on the stock. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $14.56.

Perspective Therapeutics Price Performance

NYSE CATX traded up $0.01 during midday trading on Monday, hitting $2.60. The company had a trading volume of 412,031 shares, compared to its average volume of 985,297. The firm has a 50-day moving average price of $3.14 and a 200-day moving average price of $7.20. Perspective Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.05.

Hedge Funds Weigh In On Perspective Therapeutics

Large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its stake in shares of Perspective Therapeutics by 8.9% during the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after acquiring an additional 1,672 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Perspective Therapeutics by 5.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock valued at $783,000 after purchasing an additional 3,211 shares during the period. BNP Paribas Financial Markets raised its position in Perspective Therapeutics by 7.4% during the 4th quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company’s stock worth $163,000 after purchasing an additional 3,529 shares during the last quarter. Rhumbline Advisers lifted its holdings in Perspective Therapeutics by 4.5% during the 4th quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock worth $303,000 after buying an additional 4,075 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Perspective Therapeutics by 3.4% in the 4th quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company’s stock valued at $458,000 after buying an additional 4,693 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.